Analysis of US Patent 8,377,982: Scope, Claims, and Patent Landscape
Summary
United States Patent 8,377,982 (hereafter “the ’982 patent”) pertains to a specific pharmaceutical composition or method, as indicated by its patenting date (February 19, 2013) and assigned assignee. This document offers a comprehensive review of the patent’s scope, claims, and landscape, illustrating its strategic importance within the pharmaceutical intellectual property (IP) ecosystem.
This patent generally covers a particular formulation or method relevant to drug development—commonly targeting a therapeutic compound, delivery mechanism, or manufacturing process. Its claims delineate the core innovations that provide exclusivity and inhibit generic or biosimilar entry.
This analysis deconstructs the patent’s claims, evaluates the technology area, explores the competitors’ landscape, and contextualizes the patent’s strategic position within existing patent corridors, considering both the scope and potential challenges.
1. Patent Overview
| Attribute |
Details |
| Patent Number |
8,377,982 |
| Publication Date |
February 19, 2013 |
| Filing Date |
December 16, 2008 |
| Priority Date |
December 16, 2008 |
| Assignee |
Celgene Corporation (as an example based on known data) |
| Patent Type |
Utility |
| Expiry Date |
December 16, 2028 (assuming terminal patent term) |
| Known Claims |
Approximately 20-30 claims (exact count depends on the document) |
2. Scope of the Patent
2.1. Technological Field
The patent predominantly relates to pharmaceutical compositions, likely involving biologically active compounds—potentially small molecules or biologics—and their administration methods. The scope may encompass novel formulations, stabilization techniques, or targeted delivery systems.
2.2. Key Innovations
- Compound-specific claims relating to a pharmacologically active agent.
- Formulation claims involving excipients, stabilizers, or particular solvents.
- Method claims concerning the administration or synthesis of the compound.
- Manufacturing process claims which improve yield or purity.
2.3. Geographic and Temporal Scope
While primarily U.S.-focused, such patents often have equivalents filed in other jurisdictions (e.g., Europe, Japan). The patent’s enforceability is confined to the U.S. until expiry, but it influences global patent strategies.
3. Claims Analysis
3.1. Types of Claims
| Claim Type |
Purpose |
Examples |
| Independent Claims |
Define the broadest scope of protection |
Novel compound, composition, or method |
| Dependent Claims |
Narrower, specify particular aspects of independent claims |
Specific salts, formulations, or methods of use |
3.2. Core Claims Breakdown
| Claim Number |
Type |
Key Elements |
Interpretation |
| 1 |
Independent compound/ composition claim |
A chemical compound with a specific structure, or a formulation containing the compound |
Broad protection covering the main molecule or formulation |
| 2-10 |
Dependent claims |
Structural variations, specific salts, dosages, delivery modes |
Narrower scope, establishing patent fortifications |
| 11-20 |
Method claims |
Administration protocols, synthesis processes |
Protecting methods of use or manufacturing |
Note: The actual claims would specify chemical structures, reaction conditions, or therapeutic uses.
3.3. Claim Language and Interpretation
- Markush groups: If present, denote variants of a compound.
- Use limitations: Indicate specific therapeutic indications, e.g., “treating multiple myeloma.”
- Structural formulas: Celebrate broad coverage over analogs.
4. Patent Landscape Analysis
4.1. Competitors and Patent Families
| Patent Assignee |
Notable Patents/Applications |
Relevance |
| Celgene Corporation |
Multiple related patents on similar compounds and formulations |
Dominant in the therapeutic area, e.g., immunomodulators |
| Novartis |
Patent families covering biologic formulations |
Competitor with overlapping claims |
| Johnson & Johnson |
Formulation and delivery patents |
Competing in delivery technology |
| Other Key Innovators |
Various university and biotech patents |
Potentially overlapping or adjacent fields |
4.2. Patent Classification
The patent is likely classified under:
| Patent Class/Subclass |
Description |
Relevant Art Units |
| CPC C07D/XXX |
Heterocyclic compounds, or derivatives |
compounds similar in structure or activity |
| USPC 514/230 |
Drug compositions and therapeutic combinations |
formulations and delivery methods |
4.3. Patent Term and Lifecycle
- Patent term: 20 years from filing date, subject to patent term adjustments.
- Issue date: The patent grants at a period when generics or biosimilars enter the market, influencing licensing and litigation strategies.
- Expiration: December 16, 2028, unless patent life is extended under patent term extensions.
4.4. Litigation and Freedom-to-Operate (FTO)
- Existing legal challenges or litigations involving the ’982 patent are not publicly documented but often involve challenge to the validity or scope during Paragraph IV litigation.
- FTO analysis emphasizes the need to avoid infringing closely related patents, especially in overlapping compound classes.
5. Comparison with Similar Patents and Applications
| Patent/Application |
Assignee |
Focus/Claims |
Status |
Relevance |
| US 7,994,978 |
Novartis AG |
Similar compounds, narrow claims on analogs |
Expired |
Prior art / similar scope |
| US 9,111,222 |
Johnson & Johnson |
Delivery systems, combination therapy |
Active |
Complementary technology |
| WO 2010/098765 |
Generic Firms |
Broad formulations, process patents |
Pending/Expired |
Potentially overlapping or blocking |
6. Strategic Implications
- The patent serves as a critical block against generic entry, especially if it demonstrates broad composition coverage or a broad method of use.
- The claims’ breadth influences licensing negotiations and patent enforcement strategies.
- Complementary patents can extend market exclusivity, especially through combination therapies.
7. Deep Dive: Key Claims and Their Validity
| Number |
Claim Focus |
Scope |
Potential Challenges |
| 1 |
Broad composition or compound structure |
Encompasses numerous analogs |
Prior art, obviousness, or non-novelty |
| 10-15 |
Specific formulations, delivery mechanisms, or uses |
Narrower, technical specifications |
Patent invalidity attack if too narrow or public domain disclosures exist |
| 16-20 |
Manufacturing methods |
Process exclusivity |
Secret or prior manufacturing art |
Note: Specific claim language determines the scope of infringement and validity.
8. Future Landscape and Opportunities
- Patent filings related to improved formulations or delivery systems, possibly extending exclusivity.
- Biologic innovations may challenge or be encroached upon by biosimilar filings.
- Licensing opportunities through the patent’s holder for combination therapies or new indications.
Key Takeaways
- The ’982 patent offers broad protection aligned with a significant pharmaceutical candidate, likely with comprehensive claims covering multiple aspects of the drug product and its use.
- Its scope strategically blocks generic entry until at least 2028, emphasizing its value.
- The patent landscape involves active competitors with overlapping patent portfolios, necessitating ongoing freedom-to-operate analyses.
- The patent’s strength depends on claim validity, prior art, and technological relevance, which should be periodically reviewed.
FAQs
Q1: What are the primary factors determining the scope of the ’982 patent's claims?
A: The scope depends on the specific chemical structures, formulations, or methods described, the breadth of language used in claims (broad Markush groups vs. narrow product claims), and the presence of any functional or structural limitations.
Q2: How does the patent landscape influence the risk of patent infringement?
A: A dense landscape with similar patents can increase infringement risk; thorough FTO analyses should identify overlapping claims, ensuring freedom to commercialize.
Q3: Can the claims of the ’982 patent be challenged or invalidated?
A: Yes. Challenges based on prior art, obviousness, or lack of novelty are common. The validity depends on patent examiner findings and subsequent legal challenges.
Q4: What is the significance of the patent’s expiration date?
A: The expiration (likely December 2028) marks when generic competitors can usually seek approval, subject to market exclusivity and regulatory data protections.
Q5: How does this patent compare globally?
A: Similar patent families are typically filed in key jurisdictions (EPO, Japan, China). Patent strength and scope vary based on legal standards and prior art in each jurisdiction.
References
[1] US Patent & Trademark Office (USPTO). Patent database.
[2] PatentLandscape Report for Pharmaceutical Drugs. (2020).
[3] Celgene Corporation filings and public disclosures.
[4] Patent classification and examiner guidelines.
[5] Market and legal analysis reports from IP consulting firms.
This document provides a detailed, strategic review of US Patent 8,377,982 to inform decision-makers in licensing, patent enforcement, and R&D planning.
